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Opinion statement
Allergen-specific immunotherapy (AIT) is the only treatment of IgE-mediated allergies so
far that has a sustained effect on clinical symptoms and can modify the course of the
disease. It is an allergen-specific treatment and therefore requires the correct identifica-
tion of the disease-causing allergens. Furthermore, AIT is a time-consuming treatment for
which the efficacy is dependent on several factors. Therefore, diagnostic tests and
biomarkers are needed that facilitate (1) selection of the correct allergens according to
the patient’s individual sensitization profile and (2) to monitor the effects of AIT. This can
provide support for the decision to continue, modify, or discontinue vaccination. One
significant mechanism of action of AIT is the induction of allergen-specific antibodies that
compete with IgE for the binding to allergen molecules, hence referred to as blocking
antibodies. It was shown in several studies that the induction of blocking antibodies by
AIT, and their specificity can be measured by allergen microarrays. Inhibition of allergen-
specific IgE binding by blocking antibodies can also be determined by microarrays and is
associated with changes in clinical parameters or other in vivo and in vitro assays
demonstrating efficacy of AIT. Furthermore, allergen microarrays allow determination of
IgE sensitizations towards a comprehensive set of allergen molecules and therefore are
well suited for identifying the disease-causing allergens for correct prescription of AIT.
Thus, diagnostic tests based on microarrayed allergens can be useful in determining the
correct prescription of AIT and can be used to monitor efficacy of AIT.
* The Author(s) 2016. This article is published with open access at Springerlink.com
Introduction
During the last decades, the prevalence of IgE-associated
allergies increased worldwide, affecting currently mil-
lions of patients, some of whom suffering from severe
or even life-threatening conditions [1–7]. Analysis of
approximately 6500 sera from population-based Euro-
pean birth cohorts in the course of the MeDALL project
[8] indicates an even higher percentage of sensitized
children which most probably will lead to higher prev-
alence of allergic disease in the decades to come. Symp-
tomatic medications like antihistamines, mast cell stabi-
lizing agents, leukotriene receptor antagonists or, in
more severe cases, corticosteroids or anti-IgE antibodies
only have short-term effects and need to be adminis-
tered regularly which causes considerable costs and bur-
den to the patients due to adverse effects of the drugs.
Allergen immunotherapy (AIT) is a cost-effective thera-
py and, so far, the only treatment that can yield
sustained symptomatic improvement [9]. However,
there are several factors thatmay hamper clinical efficacy
of AIT, someofwhich are directly associatedwith the use
of allergen extracts for vaccination. Due to the great
variability of natural allergen sources regarding allergen
composition and concentration, allergen extracts used
both for diagnosis and therapy show considerable vari-
ation when products from different producers or
different batches are compared [10–14]. In addition,
specimens from particular allergen sources may contain
clinically relevant allergens but their amounts are insuf-
ficient, e.g., Der p 23 fromhouse dustmite [15], or are in
general difficult to extract, like material from fungi [16,
17]. Therefore, vaccines for AIT that are based on natural
allergen extracts often do not cover the individual sensi-
tization profile of the patient in terms of allergen com-
position and thus, treatment may fail in such cases.
However, even if the vaccine does contain all clinically
relevant allergen molecules it is not possible to predict
for the individual patient if AIT is likely to induce a
beneficial immune response because certain allergens
may exhibit low immunogenicity and/or there may be
non-responders among patients.
Allergen immunotherapy is a treatment which re-
quires considerable patient time and health care re-
sources. Albeit in general it is very safe, there is the risk
of severe systemic side effects [18]. It has been suggested
that accuracy of prescription of AIT can be improved by
component resolved diagnosis [19–21] which was con-
firmed by an increasing number of studies [22–24].
Therefore, diagnostic algorithms based on molecular
diagnosis have been developed for several respiratory
and venom allergies [25–27].
Evidence for the role of blocking antibodies for clinical efficacy
of AIT
In 1911, the first allergen-specific immunotherapy (AIT) study was published
by Leonard Noon [28]. His work was inspired by the demonstration that
antisera can be raised against pollen allergens in animals which could neutralize
their allergenic activity when applied to allergic patients, a finding which
already emphasized the importance of protective antibodies for preventing
allergic symptoms [29]. Carl Prausnitz and Heinz Küstner demonstrated that
reactivity to allergens can be specifically transferred by intradermal injection of
sera obtained from allergic subjects into the skin of healthy individuals or of
subjects allergic to other allergen sources [30]. This experiment identified a
serum factor specific for allergens which later was identified as immunoglobu-
lin E as being responsible for allergic reactions [31] and paved the ground for
further investigations of mechanisms underlying AIT. Using the approach of
passive serum transfer of Prausnitz and Küstner, Cooke showed that AIT in-
duced a blocking antibody response in treated patients which could suppress
allergic reactions [32]. In these experiments, sera from allergic patients were
collected before and after subcutaneous immunotherapy and injected into the
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skin of non-allergic subjects. Skin tests performed in these pre-treated areas
showed that sera obtained after AIT were blocking skin reactivity in an allergen-
specific manner. Based on these observations, Cooke et al. concluded that there
is Bthe development under treatment of a peculiar blocking or inhibiting type of
immune antibody that prevented the action of allergen on the sensitizing
antibody,^ hence coining the concept of blocking antibodies as a Btransferable
protective substance^ that accounts for clinical improvement after AIT [32].
Loveless characterized the blocking antibodies as IgG antibodies [33]. Blocking
antibodies are immunoglobulins of any isotype other than IgE,mostly IgG1 and
IgG4 [34, 35], to some extent also IgG2 and IgA [36], that compete with IgE for
the binding to the same allergen molecule (Fig. 1) and therefore prevent
allergen-induced activation of mast cells and basophils [37], as well as IgE-
facilitated allergen presentation [38, 39]. In a pivotal study, Loveless could
demonstrate the correlation between the degree of clinical improvement after
AIT and the blocking capacity of sera obtained from patients after vaccination
by calculating the amount of allergen that can be neutralized perml of such sera
in skin studies [40].
In an attempt to develop laboratory tests that mimic the reduction of in vivo
sensitivity to allergens, the histamine-release test was used to demonstrate the
development of blocking antibodies in the course of AIT by their ability Bto
react with antigen in the fluid phase, thereby diminishing the anaphylactic
release of histamine from leukocytes,^ in addition to tests showing the compe-
tition of blocking antibodies with allergen-specific IgE for binding to allergen
[41]. These early findings suggest that the measurement of blocking antibodies
which interfere with the IgE recognition of allergens can be used as universal
biomarker to assess the clinical efficacy of AIT.
Limitations of the assessment of blocking antibodies as
biomarker for clinical efficacy of AIT
There are several reasons why the assessment of blocking antibodies cannot
totally mimic clinical efficacy of AIT. First of all, allergic patients suffer not only
Fig. 1. Blocking versus non-blocking antibodies. Non-blocking allergen-specific IgG antibodies (gray) recognize different epitopes
than IgE antibodies (red) specific for the same allergen molecule and therefore both IgE and IgG can bind simultaneously to the
same allergen. In contrast, blocking IgG antibodies (blue) bind to the same region as allergen-specific IgE and therefore,
competition between IgE and IgG for binding to the same molecule occurs.
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from immediate allergic reactions caused by allergen/IgE-inducedmast cell and
basophil activation. In fact, it has been shown that non-IgE-reactive allergen
peptides can also cause allergic inflammation by activation of allergen-specific T
cells [42]. Furthermore, AIT using allergen extracts which are generally derived
from natural sources are often of poor quality and do not induce protective
antibody responses against each of the allergens recognized by the individual
patient. Additionally, one must bear in mind that only a portion of IgG
antibodies induced by allergen extracts is directed against allergens and has
the ability to block IgE binding [39]. Moreover, pivotal endpoints used as
markers for clinical efficacy of AIT such as symptom and medication scores
are influenced by allergen exposure and thusmay vary with the extent of natural
allergen load, epithelial barrier function and individual habits of the patient
and therefore may not reflect efficacy of AIT. Furthermore, other aspects like
prediction of clinical efficacy of AIT and sustainability of its effects, as well as
availability of biomarkers providing a rationale on how to proceed in cases of
no or poor improvement of the patient’s clinical condition after AIT are still
unmet needs [43, 44].
It is therefore not surprising that there is an ongoing search for better
biomarkers but the results to date are not very promising. Some authors have
investigated the association of the clinical outcome of AIT with changes in
serum levels of particular cytokines, especially interleukin (IL)-10. The transient
increase in serum levels of IL-10 during the early phases of AIT was confirmed
by several authors [45, 46], but no clear and significant association with clinical
efficacy could be demonstrated so far [47]. This is not unexpected since changes
in cytokine levels do not reflect tolerance induction to all of the components the
patient has demonstrated allergic sensitivity and thus, IL-10 is not a suitable
marker for clinical efficacy of AIT. Attempts to correlate clinical parameters with
therapy-induced changes in allergen-specific antibodies of certain classes or
subclasses (IgE, IgG, IgG1, IgG4, or IgA) yielded conflicting results [48–52].
Ratios of allergen-specific IgE to total IgE [53] or of allergen-specific IgG4 to IgG1
[54] showed better results in terms of prediction of or correlation with clinical
outcome in some studies which, however, could not be confirmed in subse-
quent trials. Likewise, efforts to adopt techniques for assessing reactivity of
allergen-specific T cells for the monitoring of AIT did not prove suitable for
routine in vitro tests and do not reflect immediate-type symptoms caused by
mast cell and basophil activation [55, 56].
In vivo surrogate markers for clinical efficacy of AIT
There are several in vivo tests that were suggested for monitoring of AIT, e.g.,
nasal, bronchial, or conjunctival provocation and controlled allergen exposure
in challenge chambers [57]. In vivo tests offer the possibility to investigate the
improvement of patients in the course of AIT in a longitudinal manner by
comparing sensitivity before and after treatment, and it has been shown that
meaningful differences can also be demonstrated between actively and placebo-
treated patients even in small groups of subjects. However, these in vivo tests are
laborious, require proper equipment and experience. They are suitedmainly for
clinical trials rather than the assessment of individual patients in clinical rou-
tine. There is therefore a demand for simple laboratory tests which can be used
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to assess the effects of AIT on allergen-specific immune responses. Such tests are
needed because they help to understand why certain patients do not respond to
treatment, for example, by revealing lack of induction of an IgG response to
allergens against which the patient is sensitized. This is an important piece of
information since AIT is a time-consuming treatment conducted over several
years to ensure sustainable effects, and it may also cause side effects. Lack of
induction of a protective immune response by a certain allergen extract can thus
be detected which allows to discontinue or adjust the treatment.
Towards blocking antibodies as biomarker for the effect of AIT
There are several possible ways to measure the blocking effect of AIT-induced
antibodies as a marker for the AIT effects on IgE-mediated mast cell and
basophil activation, as well as on IgE-mediated T cell activation. In fact, different
types of cell-based in vitro assays were developed that mimic the effects of
blocking IgG on IgE-mediated mechanisms occurring in vivo, like basophil
activation tests performed in the presence of IgG [58–61], inhibition of
allergen-induced T cell proliferation and cytokine release using patients’ cells
[38] or the facilitated allergen binding (FAB) assay that uses a CD23-expressing
B cell line together with an IgE-containing indicator serum [62, 63]. Using these
tests, the effects of blocking antibodies on immediate-type effector cell re-
sponses that are based on mast cell and basophil activation, as well as their
impact on late phase responses by T cell activation can be studied.
Schmid et al. were successful in demonstrating that a favorable clinical
outcome can be predicted by early reduction in basophil sensitivity during
AIT to grass pollen [64], and James et al. in demonstrating that the persistence
of the blocking effect of allergen-specific IgG antibodies in the FAB test corre-
lates with sustained clinical benefit from AIT [34]. However, in contrast to
serological tests, these assays are laborious and difficult to standardize [63,
65] and therefore, implementation for routine monitoring of AIT may be
difficult and requires defined allergen preparations.
In this context, it must be emphasized again that, since any allergen extract
used for AIT may induce IgG to allergens as well as to non-allergenic molecules
contained in the vaccine, quantification of IgG response to the complete vaccine
is ofminor significance for the assessment of a therapeutically relevant immune
response to AIT treatment [39]. The development of tests using purified recom-
binant or natural allergen molecules allowed for specific quantification of the
fraction of IgG directed against the allergen proper, which improved accuracy of
monitoring. However, it was not possible to differentiate blocking from non-
blocking IgG antibodies [48, 52]. The reason for that is that in most tests used
for the quantification of allergen-specific antibodies, like ImmunoCAP (Ther-
mo Fisher Scientific, Uppsala, Sweden) or ELISA, an excess of allergen mole-
cules is employed when compared with levels of antibodies in patients’ sera
which bind to that particular allergen (Fig. 2). The ImmunoCAP test, for
instance, comprises 1–2 μg of allergen. In the case of Bet v 1 from birch pollen,
for example, 1 μg corresponds to approximately 35,400 billion molecules
(Fig. 2, right). If a serum sample with, e.g., 100 UA/ml (units allergen-specific
IgE per milliliter) of Bet v 1-specific IgE (equals approximately 242 ng/ml [66])
is tested, 50 μl of serum that are applied to the test system contain ca. 40 billion
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molecules of Bet v 1-specific IgE (Fig. 2, left). Hence, the allergen-to-IgE ratio in
the test system amounts to ca. 900:1 or, in other words, every single IgE
molecule in that serum sample has almost 900 binding sites to Bchoose from^
for binding to the ImmunoCAP. This surplus of binding sites allows almost
Fig. 2. Example of the calculation of the ratio of allergen-specific IgE and allergen molecules in a test system using allergen excess
(e.g., ImmunoCAP).
Fig. 3. Samples that are devoid of blocking IgG antibodies (blue) yield similar results for detection of IgE (red) in serological testing
by microarray (a) and by tests that employ a large amount of allergen (yellow) per assay, like ImmunoCAP (c). By contrast, in
presence of blocking IgG, competition between IgE and blocking IgG antibodies for binding to the same allergen molecule reduces
IgE levels detected by microarray containing low amounts of allergen (b) but not in tests using large quantities of allergen (d).
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quantitative IgE binding (Fig. 3c), even in presence of high titers of blocking IgG
antibodies (Fig. 3d) [67•]. Therefore, these tests are well suited for the quanti-
fication of humoral immune responses to allergen molecules, both of the IgE
and IgG isotype.
However, amounts of allergen that are incorporated by patients following
allergen contact are extremely low [68–70] and, accordingly, competition be-
tween IgE and IgG for the limited number of binding sites takes place. This is
why tests employing an excess of allergenmolecules for antibodymeasurement
do not reflect in vivo conditions which is an important reason for the poor
correlation of test results with clinical outcome that is observed in many
patients.
In an attempt to measure the blocking effect of AIT-induced non-IgE anti-
bodies, Würtzen et al. [71] adopted a test protocol for IgE detection (Advia
Centaur, Siemens Healthcare GmbH, Erlangen, Germany). In this single-plexed
liquid phase assay, patient’s IgE is captured by paramagnetic beads that are
covered with anti-IgE antibodies as a first step. Allergen-specific IgE is then
quantified by addition of a molar excess of labeled allergen [72]. By omitting
the washing step that removes serum IgG prior to additon of allergen, the
authors could measure the blocking effect of therapy-induced IgG on IgE
binding to allergens. Results obtainedwith themodified protocol showed good
correlation with changes in histamine release and FAB assays, indicating that
serological tests can yield results that are equivalent to those from cell-based
systems. However, no significant correlationwith clinical parameters like symp-
tom or medication scores could be demonstrated, presumably due to the
limiting factors mentioned above that apply for assays measuring blocking
antibodies as surrogate for clinical efficacy of AIT [71].
Allergen microarrays can detect the induction of blocking
antibodies
In 2002, Hiller et al. published the first study illustrating the possibility of
employing protein microarray technology for allergy diagnosis [73]. At that
time, most of the prevalent allergen molecules were available as well defined
recombinant or purified natural proteins and so the first allergen microarray,
Immuno Solid-phase Allergen Chip (ISAC, VBC Genomics, Vienna, Austria,
today Thermo Fisher, Uppsala, Sweden), was Bborn^ and soon approved for
allergy diagnosis. This multiplexed test allows the detection of IgE or IgG
antibodies to a large number of allergen components in one step, consuming
only minute amounts of serum. Since the release of the first version of ISAC,
substantial improvements were made regarding the allergens included on the
array, coupling chemistry and detection systems so that the sensitivity of the test
could be further increased. The clinical value of multiplexed serological tests for
component resolved diagnosis (CRD) in terms of improved accuracy of diag-
nosis and prescription of AIT has been reviewed [22, 74].
One major difference between microarrays and most other serological test
systems is that on an allergen chip, the amount of protein immobilized per spot
lies in the range of 100 fg (i.e., approximately 1 attomol or 600,000 molecules
per spot). This is approximately 10,000,000 times less when compared with,
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e.g., the ImmunoCAP system, where 1–2 μg of allergen is used per assay. Due to
this markedly reduced number of allergen molecules per test, microarrays
mimic in vivo conditions more closely where also only few allergen molecules
enter via the skin or the mucosa and combine with IgE and IgG antibodies. On
average, around 20 pollen grains are found in the nasal mucosa after 30 min of
Bnatural^ exposure during the pollen season [68] (Fig. 4). For example, a birch
pollen grain contains approximately 6 pg of Bet v 1 [75]. Allergen release from
pollen into ambient air allowed to calculate an average discharge of around
3.2 pg of Bet v 1 per birch pollen grain [69]. Similar results were found for
timothy grass pollen with 2.6 pg of Phl p 5 released per pollen grain [70].
Coupled to small airborne particles derived from the pollen themselves, aller-
gen molecules can also reach lower airways [75]. Considering the fact that only
a few percent of allergen molecules will permeate the mucosa [76], these
findings indicate that ratios between levels of allergen molecules and allergen-
specific IgE and IgG that occur at sites of allergen incorporation through
mucosal surfaces after discharge of allergens by inhaled pollen grains or follow-
ing allergen-delivery by small inhaled particles, seem to be astoundingly well
reflected by serological testing using allergen chips. The same is true for skin
prick testing where an average volume of 16 nanoliters enters the skin [77]
196 Specific Immunotherapy (L Cox, Section Editor)
Fig. 4. Approximation of allergen uptake by the nasal mucosa during Bnatural^ seasonal pollen exposure.
which leads to incorporation of around 10–300 pg of allergen, depending on
allergen-concentration in the test solution [11, 12].
Hence, like in vivo, where blocking antibodies may lead to inhibition of IgE
binding to allergenmolecules which causes reduction ofmast cell and basophil
activation in tissues [32, 33, 35], IgE-signal intensities measured by allergen
chips may be reduced by blocking antibodies as well (Fig. 3a, b). This was
recently demonstrated in a study using a customized version of ISAC, the
MeDALL chip [67•]. In these experiments, a monoclonal human IgE antibody
specific to Bet v 1, the major birch pollen allergen, was mixed with increasing
concentrations of a monoclonal IgG antibody sharing identical variable do-
mains, i.e., binding to exactly the same epitope. These experiments clearly
showed that the allergen chip can detect the blocking effect of allergen-
specific IgG with high sensitivity, even in cases of low levels of specific IgE,
which is in contrast to the ImmunoCAP system where no changes were ob-
served up to a 100-fold excess of blocking IgG. Using the MeDALL chip, it was
also proven that the sensitivity of microarrays for IgE detection is equal or even
superior to technologies using allergen excess [67•, 78].
Until now, other platforms for multiplexed serological allergy diagnosis
have been developed, e.g., FACS-based microbead arrays [79], Microtest (Lon-
don, UK), MARIA (Indoor Biotechnologies, Virginia, USA), and others, some of
which already were approved for clinical use. However, the capacity of these
tests to measure the blocking effect of AIT-induced non-IgE antibodies remains
to be investigated.
Monitoring of AIT by allergen microarray
Based on the strong evidence for the role of blocking IgG in AIT and on the
aforementioned findings on the detection of the blocking effect of IgG by
microarray, results from clinical trials were published recently that corroborate
the potential usefulness of allergen microarrays for the monitoring of AIT.
Wollmann et al. reported results from IgE and IgG measurements by
ImmunoCAP and ISAC in sera from patients who were vaccinated with two
hypoallergenic Bet v 1-derivatives [80••]. Both serological test systems were
concordant in detecting the induction of allergen-specific IgG in treated sub-
jects, but differed in results from IgE measurements. While in sera obtained
from treated individuals, a boost of Bet v 1-specific IgE was observed by
ImmunoCAP, analysis of the same samples by ISAC revealed a decrease of Bet
v 1-specific IgE, indicative for the blocking activity of AIT-induced IgG. In this
AIT trial, nasal provocation tests were performed as a surrogate for clinical
sensitivity. For the population studied, a drop in specific IgE had high predictive
value for an increase in nasal tolerance in provocation testing.
In another clinical study, Schmid et al. analyzed sera from 24 grass-pollen-
allergic patients suffering from allergic rhinoconjunctivitis, 18 of whom were
subjected to subcutaneous immunotherapy (SCIT) with grass pollen extract and
6 receiving symptomatic medication only [81••]. In accordance with previously
published data, an increase in IgG4 and a decrease in IgE specific to grass pollen
allergens were demonstrated by ISAC measurements whereas in ImmunoCAP
both IgE and IgG4 rose. The authors observed that in the treated subjects baseline
levels and reactivity patterns of grass pollen allergen-specific IgE allowed the
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prediction of the specificities and the magnitudes of IgG4 responses to the
respective grass pollen components. In addition, strong correlations between
IgE and IgG4 levels that were measured by ISAC with findings from basophil
activation tests, FAB assays and with symptom scores were demonstrated [81••].
In an approach to further dissect the immune response to allergen mole-
cules, microarrays comprising overlapping peptides that cover the complete
amino acid sequence of different allergen molecules were developed. This
technology was used by Vickery et al. for monitoring of an oral immunotherapy
(OIT) trial aiming at the induction of tolerance to peanut allergens [82•].
During 4 years of OIT, patients mounted an increasing spectrum of IgG4
specificities with growing signal intensities that was paralleled by a decrease
of IgE levels but not by changes of IgE-reactivity patterns. Furthermore, the
authors observed an induction of IgG to particular peptides that were described
in a previous study to distinguish peanut-sensitized subjects with symptoms
from sensitized individuals without clinical symptoms upon peanut ingestion
[83], indicating that it may be possible to precisely predict the success of AIT by
peptide microarrays. The same principle was applied by Savilahti et al. in
patients suffering from cow’s milk allergy to predict the natural course of the
disease [84], to forecast the outcome of OIT to cow’s milk allergy and to
differentiate serologically between successfully treated patients and non-
responders [85••]. These results could be replicated by Martínez-Botas et al.
who, in addition, could identify IgE-reactivity patterns to peptides from cow’s
milk allergens that allowed to distinguish high- from low-risk patients in terms
of frequencies of allergic reactions during treatment, consumption of rescue
medication, and time needed to achieve clinical improvement [86].
These studies provide evidence for the feasibility of microarray-based sero-
logical findings to be used as surrogate marker for the monitoring and the
prediction of clinical efficacy of AIT. Even though data are still restricted to few
allergen sources, it was already demonstrated that the concept can be applied to
both respiratory and food allergies.
For the serological monitoring of AIT, availability of baseline values is
essential to evaluate therapeutically induced changes in antibody-reactivity
patterns and levels. Therefore, a serum sample should be collected from
every patient before start of AIT and stored in a freezer. This would enable
the clinician to evaluate the development and alteration of the immune
response to the allergens at a later point. This could be particularly useful
in patients for which immunotherapy has not achieved the desired clinical
effects, i.e., lack of clinical improvement or even worsening of symptoms.
For example, detection of a decrease of IgE signals, albeit still too weak,
should endorse the physician’s decision to pursue AIT, aiming at a further
reduction of IgE levels detected. By contrast, no change in IgE levels at all
or absence of IgG induction to those allergen molecules the patient is
sensitized to could indicate that the patient’s immune system does not
respond to the vaccine or a lack of particular allergen components in the
extract used for treatment [12]. These findings could help the clinician to
decide if AIT should be continued, modified, e.g., by using a vaccine from
a different producer, or even discontinued in the individual patient.
Allergen microarrays are continuously subjected to technical modifica-
tions that shall further enhance their clinical versatility. First, by optimi-
zation of the panel of allergen components that are represented on the
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chip, accuracy of prescription of AIT will be even improved. Knowing the
patient’s molecular sensitization pattern may allow to estimate the pro-
pensity of AIT to be beneficial, especially in case of vaccination with
extracts that are frequently devoid of particular, clinically relevant aller-
gens as those from house dust mite [14]. Second, by employing peptides
that replace or supplement complete allergen molecules on the microar-
ray, immune responses to those epitopes that are involved in the initi-
ation of symptoms could be distinguished from clinically less relevant
IgE reactivities. Third, advances in chip production and in protocols for
serum analysis should allow reduction of average costs per analysis.
In summary, if microarray-based algorithms for the prediction and
monitoring of the course of AIT can be established and replicated for
additional allergen sources, it will be possible to distinguish patients
who are likely to benefit from AIT from those who most probably will
not. If this can be achieved early in the course of AIT or even before
start of vaccination, this patient-tailored approach is a classical example
of precision medicine that would help to improve prescription and
monitoring of AIT and thus reduce the burden of unnecessary risks of
adverse effects and costs and to safe time, hence creating benefits for
patients, doctors, and the health care system.
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